Modified Nucleosides
7,8-dihydro-8-oxo-7-allyl-guanosine
Quick view. We supply 7,8-dihydro-8-oxo-7-allyl-guanosine as a specialty product for nucleic acid chemistry and oligonucleotide research workflows. CAS 121288-39-9. Catalog target purity: Specification on request.
Product profile
7,8-dihydro-8-oxo-7-allyl-guanosine is classified as nucleoside or protected nucleoside intermediate (Formula C13H17N5O6; molecular weight 339.306).
7,8-dihydro-8-oxo-7-allyl-guanosine can serve as a starting material, protected intermediate or analytical comparator in nucleoside and nucleotide route development.
For 7,8-dihydro-8-oxo-7-allyl-guanosine, reported solubility: Soluble in DMSO (up to 25 mg/ml). Storage: Desiccate at +4°C.
Names and search terms
Confirmed or normalized name variants
- loxoribine
- RWJ 21757
- 7-ALLYL-7 8-DIHYDRO-8-OXOGUANOSINE 95
- 7,8-Dihydro-8-oxo-7-(2-propenyl)guanosine
- Guanosine, 7,8-dihydro-8-oxo-7-(2-propenyl)-
- Guanosine, 7,8-dihydro-8-oxo-7-(2-propen-1-yl)-
- 7,8-dihydro-8-oxo-7-allyl-guanosine, Loxoribine
- 7-ALLYL-7 8-DIHYDRO-8-OXOGUANOSINE 95 USP/EP/BP
Useful catalog search terms
- CAS 121288-39-9
- Nucleoside or protected nucleoside intermediate
- Modified Nucleosides
Physicochemical data
| InChI | 1S/C13H17N5O6/c1-2-3-17-6-9(15-12(14)16-10(6)22)18(13(17)23)11-8(21)7(20)5(4-19)24-11/h,5,7-8,11,19-21H,1,3-4H2,(H3,14,15,16,22)/t5-,7-,8-,11-/m1/s |
|---|---|
| InChIKey | VDCRFBBZFHHYGT-IOSLPCCCSA-N |
| SMILES | NC1=NC2=C(N(CC=C)C(=O)N2[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C(=O)N1 |
| Melting point | 227-230 °C(lit.) |
| Density | 1.92±0.1 g/cm3(Predicted) |
| pKa | 10.29±0.20(Predicted) |
| Form | White to off-white solid. |
| Color | White |
Release documentation
The current specification defines the analytical method and acceptance criteria; the released lot result is reported on the CoA.
Additional HPLC, MS or NMR documentation can be agreed during technical review where available.
Additional application examples
- Typical work includes protection/deprotection studies, phosphorylation or phosphitylation route scouting and impurity identification.
- The material can support medicinal-chemistry analog preparation and process-development feasibility studies.
Related products
(S)-cEt-rA
Modified Nucleosides · CAS: 1197033-34-3
BX-OP-0069S-Adenosylmethionine (SAM)
Modified Nucleosides · CAS: 485-80-3
BX-MN-0185(R-/S-) 5-Carbamoylhydroxy methyluridine
Modified Nucleosides · CAS: N/A
BX-MN-0186(R-/S-)5-(1-Hydroxy)(methoxycarbonyl)methyl uridine
Modified Nucleosides · CAS: N/A
BX-MN-0187(R-/S-)5-Carboxyhydroxymethyl uridine
Modified Nucleosides · CAS: N/A
BX-MN-0719(R)-N-(2,3-dihydro-1H-indenyl)adenosine
Modified Nucleosides · CAS: 96392-15-3
Frequently asked questions
Can the package size for 7,8-dihydro-8-oxo-7-allyl-guanosine be customized?
Yes. Share the initial quantity, expected future scale, delivery timeline and packaging preference for review.
What information should be included in a quote request?
Quote catalog number BX-MN-0219 and CAS 121288-39-9, the intended research workflow, required quantity and any additional HPLC, MS or NMR documentation needed.
Product-family literature
The publications below provide peer-reviewed context for the Modified Nucleosides product family and its named chemistry.